# Inhibikase Therapeutics, Inc.: filings

IKT · Nasdaq · CIK 1750149 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ikt.md) · [Financials](/companies/ikt/financials.md) · [Filings](/companies/ikt/filings.md) · [Insiders](/companies/ikt/insiders.md)

## Reports and events: 122 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 85, 8-K 68, CORRESP 22, 3 20, SCHEDULE 13G/A 18, 10-Q 17, UPLOAD 11, SC 13G 10, EFFECT 9, S-1/A 9, 424B5 8, DEF 14A 8, DEFA14A 8, PRE 14A 7, 10-K 6, S-1 5, S-8 5, SC 13D 5, 424B3 4, 4/A 4, ARS 4, S-3 4, SCHEDULE 13G 4, 3/A 3, 10-K/A 2, 424B4 2, 8-K/A 2, D 2, DRS 2, DRSLTR 2, SC 13G/A 2, 8-A12B 1, CERT 1, DEFR14A 1, DRS/A 1, POS AM 1, RW 1, S-1MEF 1, S-3/A 1, SC 14F1 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-20 | 20:57 ET | [8-K](/filings/0001193125-26-426811.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-426811 |
| 2026-09-08 | 20:41 ET | [8-K](/filings/0001193125-26-385293.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-385293 |
| 2026-08-26 | 20:05 ET | [8-K](/filings/0001193125-26-368296.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001193125-26-368296 |
| 2026-08-11 | 20:17 ET | [10-Q](/filings/0001193125-26-344707.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344707 |
| 2026-08-11 | 20:08 ET | [8-K](/filings/0001193125-26-344623.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344623 |
| 2026-07-29 | 20:05 ET | [8-K](/filings/0001193125-26-323651.md) | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-323651 |
| 2026-07-23 | 12:32 ET | [8-K](/filings/0001193125-26-313400.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-313400 |
| 2026-07-14 | 12:11 ET | [8-K](/filings/0001193125-26-302580.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-302580 |
| 2026-06-29 | 10:05 ET | [8-K](/filings/0001193125-26-286747.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-286747 |
| 2026-05-12 | 20:39 ET | [10-Q](/filings/0001193125-26-219641.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219641 |
| 2026-05-12 | 20:31 ET | [8-K](/filings/0001193125-26-219610.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219610 |
| 2026-04-30 | 20:05 ET | [DEF 14A](/filings/0001193125-26-197177.md) | Proxy statement, period 2026-06-26 | 0001193125-26-197177 |
| 2026-04-07 | 12:09 ET | [8-K](/filings/0001193125-26-144582.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-144582 |
| 2026-03-26 | 20:32 ET | [10-K](/filings/0001193125-26-126371.md) | Annual report, period 2025-12-31 | 0001193125-26-126371 |
| 2026-03-26 | 20:21 ET | [8-K](/filings/0001193125-26-126322.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-126322 |
| 2025-12-19 | 21:17 ET | [8-K](/filings/0001193125-25-326916.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-326916 |
| 2025-11-21 | 21:28 ET | [8-K](/filings/0001193125-25-291443.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-291443 |
| 2025-11-20 | 21:11 ET | [8-K](/filings/0001193125-25-289768.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-289768 |
| 2025-11-14 | 21:37 ET | [10-Q](/filings/0001193125-25-283169.md) | Quarterly report, period 2025-09-30 | 0001193125-25-283169 |
| 2025-11-14 | 21:25 ET | [8-K](/filings/0001193125-25-283075.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-283075 |
| 2025-08-14 | 21:06 ET | [10-Q](/filings/0001193125-25-180899.md) | Quarterly report, period 2025-06-30 | 0001193125-25-180899 |
| 2025-08-14 | 20:56 ET | [8-K](/filings/0001193125-25-180889.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-180889 |
| 2025-06-30 | 20:29 ET | [8-K](/filings/0001193125-25-152767.md) | 5.07 Shareholder vote results | 0001193125-25-152767 |
| 2025-05-14 | 21:29 ET | [10-Q](/filings/0000950170-25-071635.md) | Quarterly report, period 2025-03-31 | 0000950170-25-071635 |
| 2025-05-14 | 21:06 ET | [8-K](/filings/0001193125-25-119939.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-119939 |
| 2025-05-12 | 20:05 ET | [DEF 14A](/filings/0000950170-25-069152.md) | Proxy statement, period 2025-06-27 | 0000950170-25-069152 |
| 2025-04-25 | 20:05 ET | [10-K/A](/filings/0000950170-25-058693.md) | Annual report, amended, period 2024-12-31 | 0000950170-25-058693 |
| 2025-04-14 | 12:16 ET | [8-K](/filings/0001193125-25-079656.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-079656 |
| 2025-03-27 | 20:19 ET | [10-K](/filings/0000950170-25-046096.md) | Annual report, period 2024-12-31 | 0000950170-25-046096 |
| 2025-03-27 | 20:10 ET | [8-K](/filings/0001193125-25-065511.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-065511 |
| 2025-02-24 | 13:14 ET | [8-K](/filings/0001193125-25-032821.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-032821 |
| 2025-02-18 | 13:09 ET | [8-K](/filings/0001193125-25-028188.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-028188 |
| 2025-01-29 | 21:05 ET | [8-K](/filings/0001193125-25-015648.md) | 8.01 Other events | 0001193125-25-015648 |
| 2025-01-06 | 11:06 ET | [8-K](/filings/0001193125-25-001787.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-25-001787 |
| 2024-12-05 | 21:50 ET | [8-K](/filings/0001193125-24-271609.md) | 1.02 Termination of a material agreement | 0001193125-24-271609 |
| 2024-11-18 | 21:05 ET | [DEF 14A](/filings/0000950170-24-127941.md) | Proxy statement, period 2025-01-03 | 0000950170-24-127941 |
| 2024-11-14 | 13:30 ET | [10-Q](/filings/0000950170-24-126766.md) | Quarterly report, period 2024-09-30 | 0000950170-24-126766 |
| 2024-10-22 | 01:13 ET | [8-K](/filings/0001193125-24-240603.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-240603 |
| 2024-10-10 | 21:31 ET | [8-K](/filings/0001193125-24-236039.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-236039 |
| 2024-10-09 | 12:40 ET | [8-K](/filings/0001193125-24-234814.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-234814 |
| 2024-08-14 | 20:14 ET | [10-Q](/filings/0000950170-24-097022.md) | Quarterly report, period 2024-06-30 | 0000950170-24-097022 |
| 2024-08-06 | 01:21 ET | [8-K](/filings/0001193125-24-194177.md) | 5.07 Shareholder vote results | 0001193125-24-194177 |
| 2024-06-20 | 22:06 ET | [DEF 14A](/filings/0000950170-24-075675.md) | Proxy statement, period 2024-08-05 | 0000950170-24-075675 |
| 2024-06-18 | 21:27 ET | [S-1](/filings/0001193125-24-163529.md) | Registration statement | 0001193125-24-163529 |
| 2024-06-10 | 20:05 ET | [8-K](/filings/0001193125-24-158318.md) | 5.07 Shareholder vote results | 0001193125-24-158318 |
| 2024-05-20 | 12:55 ET | [8-K](/filings/0001193125-24-142317.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-142317 |
| 2024-05-15 | 21:04 ET | [10-Q](/filings/0000950170-24-060579.md) | Quarterly report, period 2024-03-31 | 0000950170-24-060579 |
| 2024-05-09 | 18:41 ET | [S-1/A](/filings/0001193125-24-135161.md) | Registration statement, amended | 0001193125-24-135161 |
| 2024-05-09 | 00:44 ET | [S-1/A](/filings/0001193125-24-134515.md) | Registration statement, amended | 0001193125-24-134515 |
| 2024-04-30 | 12:17 ET | [8-K](/filings/0001193125-24-123758.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-123758 |

Page 1 of 3. [Older](/companies/ikt/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.